Cigna Group closed 20.66% short of its 52-week high of $370.83, which the company reached on September 16th.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

California is leading the way in ensuring that determinations of medically necessary health care services are made by licensed physicians and ...

The number of victims impacted by the Change Healthcare data breach last year has nearly doubled, from 100 million to ...

Q4 2024 Earnings Call Transcript January 30, 2025 Cigna Corporation misses on earnings expectations. Reported EPS is $6.64 ...

In a report released yesterday, Ben Hendrix from RBC Capital maintained a Buy rating on Cigna (CI – Research Report), with a price target of ...

Erin Wright, an analyst from Morgan Stanley, assigned the Buy rating on Cigna (CI – Research Report). The associated price target is ...

Shares of Cigna Group slipped 6.70% to $282.98 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.53% to 6,071.17 and the Dow ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Cigna Group CEO David Cordani said the company will make investments this year to improve patient and provider experiences ...

Cigna Group shares fell sharply after the health insurer reported fourth-quarter profit that was dragged down by medical ...

According to Bloomberg, a top Cigna executive said it will prevent patients from paying the full list price for drugs, or more than their employer has contributed.